Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
This article first appeared on GuruFocus. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped roughly 21% in premarket trading after the U.S.…
Six economic flashpoints to watch out for in 2026 – The Irish Times
The global economy showed remarkable resilience in 2025 despite significant trade tensions and policy uncertainty related to US…
China’s new commercial insurance model could broaden access to Alzheimer’s drugs
ChiÂna’s new comÂmerÂcial inÂsurÂance forÂmuÂlaÂry looks to exÂpand paÂtient acÂcess to Alzheimer’s disÂease medÂiÂcines from Eli LilÂly and…
Novo’s Wegovy pill to test demand from consumers with cash
LONDON, Dec 23 (Reuters) – Novo Nordisk’s newly approved weight-loss pill version of Wegovy will be a test…
Eli Lilly’s pill solves the biggest problem with weight loss
Losing weight hasn’t quite been the hardest part of modern obesity treatment. Keeping it off is. That’s exactly…
Eli Lilly Scores Another Major Win: Time to Buy?
Eli Lilly’s next-gen anti-obesity candidate hit it out of the park in a phase 3 study. This should…
Better Buy in 2026: Pfizer or Eli Lilly?
Eli Lilly has been a dominant force in the GLP-1 market, and that looks set to continue. Pfizer’s…
Oh no, Ozempic! Eli Lilly’s New Weight-Loss Drug KOs Rival Treatments
How do you swear in Danish? Our AI chatbots are much too polite to help us out here,…
Analysis-Alzheimer’s drug hunt learns from cancer fight’s multi-target playbook
By Deena Beasley Dec 12 (Reuters) – Alzheimer’s trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their…
Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump
24/7 Wall St. Abbott Laboratories (ABT) grew revenue 6.9% with medical devices up 14.8% to $5.45B. Abbott reaffirmed…
1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Ireland dodged a bullet this year. But there’s a caveat – The Irish Times
The Irish economy dodged a bullet this year. Several of them, in fact. Back in April, we were…